ICON has been awarded a project by the U.S. FDA to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).   HABP is the second most common hospital-acquired infection and is the primary cause of death in intensive care units. ICON’s Commercialization and Outcomes group, in collaboration with the Biomarkers Consortium of the Foundation for the National Institutes of Health (FN...